Search

Your search keyword '"Wendtner, C."' showing total 467 results

Search Constraints

Start Over You searched for: Author "Wendtner, C." Remove constraint Author: "Wendtner, C."
467 results on '"Wendtner, C."'

Search Results

1. Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus

3. Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial.

6. ARTERIELLE HYPERTONIE

8. ERKRANKUNGEN DES HERZENS UND DES KREISLAUFS

9. ERKRANKUNGEN DER ATMUNGSORGANE

11. ERKRANKUNGEN DER VERDAUUNGSORGANE

12. ERKRANKUNGEN DER GEFÄSSE

13. Einführung

14. INTERNISTISCHE INTENSIVMEDIZIN

15. INFEKTIONSKRANKHEITEN

16. RHEUMATISCHE ERKRANKUNGEN

17. SCHLAGANFALL

18. ERKRANKUNGEN DER NIERE

19. A PHASE 3 TRIAL OF ACALABRUTINIB, OBINUTUZUMAB AND VENETOCLAX COMPARED TO OBINUTUZUMAB AND VENETOCLAX IN PATIENTS WITH HIGH RISK CHRONIC LYMPHOCYTIC LEUKEMIA

20. Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group

21. A second update on mapping the human genetic architecture of COVID-19

26. P641: RETREATMENT WITH VENETOCLAX AFTER VENETOCLAX, OBINUTUZUMAB +/- IBRUTINIB: POOLED ANALYSIS OF 13 PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TREATED IN GCLLSG TRIALS

29. Managing hematological cancer patients during the COVID-19 pandemic:an ESMO-EHA Interdisciplinary Expert Consensus

33. Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus

37. THE CLL‐RT1 TRIAL: A MULTICENTER PHASE‐2 TRIAL OF ZANUBRUTINIB, A BTK INHIBITOR, PLUS TISLELIZUMAB, A PD‐1 INHIBITOR, FOR PATIENTS WITH RICHTER TRANSFORMATION

38. BENDAMUSTINE, FOLLOWED BY OBINUTUZUMAB, ACALABRUTINIB AND VENETOCLAX IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): CLL2‐BAAG TRIAL OF THE GCLLSG

39. VENETOCLAX‐OBINUTUZUMAB MODULATES CLONAL GROWTH: RESULTS OF A POPULATION‐BASED MINIMAL RESIDUAL DISEASE MODEL FROM THE RANDOMIZED CLL14 STUDY

40. VENETOCLAX‐OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 4‐YEAR FOLLOW‐UP ANALYSIS OF THE RANDOMIZED CLL14 STUDY

Catalog

Books, media, physical & digital resources